EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis

Omar Saeed, Abdelrahman Saeed, Osama Barakat, Abdulaziz Bawjeh, Tuğba Saka, Tasneem Mustafa Yousif, Aeshah Mohammed Adim, Muhammed Elhadi iD, Mamas A Mamas iD

Catheterization and Cardiovascular Interventions · 2026-03 · 107 (4) · 1225-1236

DOI: 10.1002/ccd.70463 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 07.01.2026. Verfasst von Omar Saeed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, Damietta, Egypt. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Aspirin, Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor, is considered the standard of care for patients who have had percutaneous coronary intervention (PCI). This study aimed to compare indobufen‐based (DAPT) to aspirin‐based (DAPT) after PCI.

Methods

This systematic review and meta‐analysis analyzed randomized controlled trials (RCTs) and propensity‐matched cohort studies comparing indobufen (DAPT) to standard aspirin (DAPT) after PCI. We searched four databases: PubMed, Scopus, Web of Science, and Cochrane through January 2025 and updated the search in September 2025. Dichotomous data were pooled as odds ratios with 95% CIs.

Results

Our search identified 403 records; only five studies were included in the analysis. Comparing major adverse cardiac and cerebrovascular events (MACCE) between the indobufen and aspirin groups, no difference was observed (OR 1.12, 95% CI: 0.87–1.46; p = 0.38). Bleeding BARC types 2, 3, 5 were compared between the two groups, showing fewer bleeding events in the indobufen group than in the aspirin group (OR: 0.47, 95% CI: 0.24–0.95; p = 0.03).

Conclusion

Indobufen‐based (DAPT) had a lower incidence of bleeding than aspirin‐based (DAPT), with no difference between the two groups for MACCE, myocardial infarction, ischemic stroke, cardiovascular death, repeat vascularization, or stent thrombosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionAspirinPlatelet Aggregation InhibitorsDual Anti-Platelet TherapyPurinergic P2Y Receptor AntagonistsCoronary Artery DiseaseHumansTreatment OutcomeRisk FactorsMaleHemorrhageFemaleRisk AssessmentAgedMiddle AgedTime FactorsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

aspirindual antiplatelet therapy (DAPT)indobufenmajor adverse cardiac and cerebrovascular events (MACCE)percutaneous coronary intervention (PCI)

Substanzen

AspirinPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
  • Faculty of Medicine, University of Aleppo, Aleppo, Syria.
  • College of Medicine (HUCOM), Hadhramout University, Hadhramout, Yemen.
  • İstinye Üniversitesi, İstanbul, Turkey.
  • Faculty of Medicine, University of Gezira, Wad Madani, Sudan.
  • Faculty of Medicine, Sabha University, Sabha, Libya.

ORCID-Profile: Muhammed Elhadi, Mamas A Mamas

Zitieren

APA

Saeed, O., Saeed, A., Barakat, O., Bawjeh, A., Saka, T., Yousif, T. M., Adim, A. M., Elhadi, M., & Mamas, M. A. (2026). Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions, 107(4), 1225-1236. https://doi.org/10.1002/ccd.70463

Vancouver

Saeed O, Saeed A, Barakat O, Bawjeh A, Saka T, Yousif TM, et al. Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. 2026;107(4):1225-1236. doi:10.1002/ccd.70463

BibTeX
@article{Saeed2026,
  author = {Saeed, Omar and Saeed, Abdelrahman and Barakat, Osama and Bawjeh, Abdulaziz and Saka, Tuğba and Yousif, Tasneem Mustafa and Adim, Aeshah Mohammed and Elhadi, Muhammed and Mamas, Mamas A},
  title = {Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {107},
  number = {4},
  pages = {1225--1236},
  doi = {10.1002/ccd.70463}
}
Kostenlos starten →